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Abstract
The battle between man and malaria has continued for thousands of years. Antimalarial drugs are essential
weapons to fight the disease, but their efficacy is threatened by drug resistance which continues to emerge
creating a major obstacle to malaria control and jeopardizing renewed hopes for elimination. As 2016 is the
first year under WHO Global Technical Strategy for Malaria 2016–2030, it is a good time to ponder the progress
of both sides and plan for the future.
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Background
Malaria is an ancient disease that has existed for several
thousand years (as evidenced from Plasmodial DNA in
mummies [1]). It is the most important parasitic dis-
ease of man and it is still a major health problem in
tropical countries [2]. The disease is caused by hemo-
protozoa of the genus Plasmodium. These parasites are
transmitted by the bites of infected female anopheline
mosquitoes. Six malaria species are known to cause
human malaria: P. falciparum, P. vivax, P. ovale curtisi,
P. ovale wallikeri, P. malariae, and P. knowlesi [3].
According to the World Health Organisation (WHO),
around 3.2 billion people are at risk of malaria infection
and there were 214 million new cases of malaria in
2015. The African Region accounted for most cases of
malaria (88 %), followed by the South-East Asia Region
(10 %) and then the Eastern Mediterranean Region
(2 %). In the same year, 438,000 deaths from malaria
were estimated to have occurred: 90 % of these deaths
occurred in the African Region [2]. However, the true
numbers may be much higher due to health informa-
tion problems in resource-poor settings [4, 5]. Previous
study by Snow et al., using geographical and demo-
graphic data and epidemiologic models, suggested that
global falciparum malaria could be up to 50 % higher
than the number reported by WHO with 200 % higher
estimates for areas outside Africa [6]. P. falciparum is
responsible for the great majority of deaths from malaria.
Most of the fatalities are in African children. The propen-
sity for P. falciparum to cause severe disease was recog-
nized by the great Italian malariologists within a few years
of the discovery of the malaria parasite by Laveran in
1880. The dangerous characteristics of P. falciparum are
both the parasite’s unique pathogenesis, causing micro-
vascular obstruction in vital organs, and its ready ability
to develop drug-resistance. While resistance to some
antimalarials does occur in P. vivax [7–9], the other
major species infecting humans, only in P. falciparum
has resistance developed to all currently used antima-
larials, including the artemisinin derivatives [10]. This
review will summarize man’s recent struggles with malaria
with an emphasis on drug resistance in P. falciparum.
Main text
The previous battles and lessons learnt
Malaria was once prevalent throughout most of the
inhabited world including Europe and North America
[11]. The evidence for man’s attempts to fight malaria
can be dated back as far as 270 years BC in the ancient
Chinese medical record Nei Jing or the Canon of
Internal Medicine. The bark of Cinchona trees was
known as a remedy for febrile illness among Peruvian
people before it was introduced to Europe by the Jesuits
in the 1630s. Although Guttman and Ehrlich demon-
strated the antimalarial efficacy of methylene blue in 1891
[12], the development of synthetic antimalarials did not
start until after the First World War with the discovery of
plasmoquine (pamaquine) in 1924. Nevertheless, quinine
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remained the mainstay of antimalarial treatment. In the
Second World War the loss of Java and thus 90 % of
the world’s Cinchona supply to Axis forces stimulated
an enormous research effort which rediscovered
chloroquine (first synthesised in 1934 in Germany) and
led to the antifolate drugs. Together with the discovery
of the insecticidal properties of DDT (dichloro-diphe-
nyl-trichloroethane) and its implementation in anoph-
eline vector control, these drugs were the main
weapons used in the Global Malaria Eradication cam-
paign from 1955 to 1969. Malaria was eliminated from
all Europe, most of the former USSR, North America,
and many parts of South America, and Asia by the early
1970s [13]. However, misuse of antimalarial drugs, such
as in the form of medicated salt [14], and widespread
availability of low quality medicines [15] lead to the
emergence of drug resistance. Chloroquine resistance
in Plasmodium falciparum appeared almost at the same
time in Thailand in Southeast Asia (SEA) in 1957 [16]
and in Colombia in South America in 1959 [17]. Resist-
ance spread in both areas [18]. Chloroquine resistance
spread across SE Asia and India and arrived at the east-
ern seaboard of Africa in 1978 [19, 20]. In 14 years it
then spread across the entire continent. The cost of
chloroquine resistance in human lives was enormous.
The number of malaria deaths rose through the 1980s
to a peak in 2004 [21]. Chloroquine resistance had
spread throughout the malaria endemic world, such
that the distribution of chloroquine resistance was al-
most identical to that of P. falciparum by 1989 [22]. Re-
cent genetic studies analyzing microsatellite markers
surrounding the Plasmodium falciparum chloroquine
resistance transporter gene (pfcrt) have confirmed that
chloroquine resistance did spread from Asia to Africa
[23]. Using the same technique it was shown that the
main form of sulfadoxine-pyrimethamine resistance
(triple 51, 59 and 108 dihydrofolate reductase (dhfr)
gene mutations), previously believed to originate inde-
pendently from numerous sources, also spread from
SEA to Africa [24].
Mixed P. falciparum and P. vivax infections are com-
mon in areas of co-endemicity such as South [25] and
SE Asia [26, 27]. The mixed infections can either mani-
fest as a double infection at the beginning of treatment
or as a sequential illness known as cryptic infection
[25–27]. Cryptic P. vivax is believed to be a relapse
from activated hepatic hypnozoites while cryptic P. fal-
ciparum is likely from erythrocytic asexual stages not
killed by P. vivax treatment [28]. Improper treatments
from failure to recognise mixed infections can lead to
the development and spreading of drug resistance para-
sites [28].
The list of other drugs that P. falciparum has devel-
oped resistance to includes quinine [13], amodiaquine
[29], mefloquine, halofantrine, lumefantrine, atovaquone,
cycloguanil/chlorcycloguanil, sulphonamides and sul-
fones [30], piperaquine [31] and recently, artemisinin
and its derivatives [32, 33]. More information about
molecular markers of resistance and in vitro susceptibility
antimalarials can be found in a recent review by Cui and
coworkers [34] and in a website of Worldwide Antimalarial
Resistance Network (WWARN) at http://www.wwarn.org/
tracking-resistance.
Artemisinin resistance: a terrible threat
Artemisinin (qinghaosu), a traditional Chinese medi-
cine, is now the cornerstone of antimalarial therapeu-
tics. It was considered so important that the 2015
Nobel Prize for Medicine or Physiology was awarded to
Tu You You for her contribution to the discovery of
this drug. Artemisinin and its derivatives provide the
most rapid parasite clearance among known antimalar-
ial drugs. It became a new hope as, during 1990s, resist-
ance to available major antimalarial drugs such as
chloroquine and sulfadoxine–pyrimethamine worsened
across malaria endemic areas globally. Artemisinin-
based monotherapies has been widely used in western
Cambodia for more than 30 years [33]. Combination
therapy with other antimalarials of a different class was
proposed to delay the development of parasite resistance
to artemisinin [35, 36]. The pairing of rapidly-eliminated
artemisinin derivatives and the slowly-eliminated partner
drugs also shortens the course of treatment compared to
those of artemisinin monotherapies [37], thus increas-
ing adherence. Three-day artemisinin-based combin-
ation therapies (ACTs) were introduced in the mid-1990s
and shown to be highly effective and well-tolerated in
treating falciparum malaria [37]. Finally since 2006, WHO
has clearly recommended ACTs as the treatment of choice
for uncomplicated P. falciparum malaria [38]. The rela-
tively high cost of these drugs and the reluctance of do-
nors to support them limited their deployment initially,
but substantial subsidies particularly from the Global
Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)
have led to a substantial increase in ACT availability in
recent years. Despite the use of ACTs, delayed parasite
clearance suggesting artemisinin resistance was re-
ported in Thailand-Cambodia border in 2007 [32, 33].
The parasite clearance half-life was shown to be the
best in-vivo phenotypic measure of resistance. Since
then slowly clearing malaria infections, defined as hav-
ing parasite clearance half-lives > 5 h, have been de-
tected from southern Vietnam to central Myanmar
[39]. This clearance has been linked with point muta-
tions in the “propeller” region of a P. falciparum kelch
protein gene on chromosome 13, also known as kelch
13 or K13 [40]. WWARN has provided an interactive
map that shows the updated global prevalence of K13,
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The K13 Molecular Surveyor, at http://www.wwarn.org/
molecular-surveyor-k13. Using the K13 marker it is now
clear that artemisinin resistance has spread from the coast
of Vietnam to the Eastern border of India [41, 42]. Declin-
ing artemisinin susceptibility also increases the selection
pressure for the emergence of partner drug resistance due
to a greater proportion of the infecting parasites remains
[43]. While artemisinin resistance is associated with de-
layed parasite clearance or early treatment failure, long
half-life partner drug resistance is associated late treat-
ment failure [44]. Failing of partner drugs then could
lead to higher clinical malaria, poor treatment outcome
and increase the chance of spreading artemisinin-
resistant parasites [45].
Why is it that resistance to all antimalarial drug classes
seems to originate from a specific area of the world, i.e.,
Southeast Asia (SEA)?
Southeast Asia: the epicenter of drug resistance
In Southeast Asia, factors such as human migration par-
ticularly amongst young men who travel extensively in
forested areas and forest-dwelling mosquitoes may ren-
der conventional vector-control methods less effective,
resulting in a greater reliance on drugs in malaria con-
trol. Several factors in malaria endemic regions of SEA
are suitable for the selection and spread of resistant par-
asites. Being a low transmission area, many infections
are in non-immune people who become symptomatic
and seek medication [30, 46]. Lower levels of immunity
and higher parasite burdens increase the probability that
drug resistant mutants will survive [47, 48]. Antimalarial
drugs including artemisinins have been widely available
in the private sector. Problems about drug use in private
sector include drug quality, high frequency of wrong
dosing and use of monotherapy, and inadequate know-
ledge and training of service providers [49, 50]. In some
areas, these problems are almost similar among public
and private sector [51]. Counterfeit or falsified antimal-
arial drugs, often now containing a small amount of
artemisinins, can be found in markets and are widely
used [15]. Self-medication with inadequate doses or
courses of treatment or low quality medicines cause
poor treatment outcomes and lead to resistance [52].
Antimalarial drug resistance usually confers a fitness dis-
advantage upon malaria parasites, but parasites in the SE
Asian region have been exposed to several different
selective forces which has created a genetic background
that may predispose to the emergence of resistance [53].
The coming battle
It will be disastrous if artemisinin resistance reaches
India and then Africa where most of the world’s malaria
burden lies. Plans to control malaria now focus on the
elimination of malaria in the greater Mekong subregion,
the major source of drug-resistant parasites [54]. The
methods recommended are strengthening of existing
measures [54], which to date have not contained the
spread of resistance nor the emergence of new foci in
the region [41]. Containing resistance will become in-
creasingly difficult as P. falciparum develops resistance
to all antimalarial drug classes. Moreover, increasing
numbers of international travelers [55] and improved re-
gional transportation will facilitate spread of resistant
parasites. Transmission blocking by using a single low-
dose primaquine in every patient with P. falciparum in-
fection in low transmission settings without the need for
glucose-6-phosphate dehydrogenase (G6PD) testing is
now recommended by WHO [56]. Recent pharmacoki-
netic studies show that co-administration of primaquine
and some ACTs, namely dihydroartemisinin-piperaquine
[57] and pyronaridine –artesunate [58], are well toler-
ated in healthy adult subjects. No significant pharmaco-
kinetic alterations on ACTs, but increased plasma
concentrations of primaquine were observed. Although
use of primaquine in radical curative regimens requires
G6PD testing, the single low dose of primaquine as a P.
falciparum gametocytocide has proved safe and well tol-
erated in G6PD deficient individuals [59]. While the
antimalarial drug pipeline is healthier than ever before,
none of the new drugs in development will be generally
available within 4 to 5 years or, more likely, a decade.
Therefore, current containment plans must rely on exist-
ing medicines. Improved dosing regimens in special pop-
ulations such as pregnant women and children whose
pharmacokinetics and pharmacodynamics are different
from general population [60, 61] will reduce the selective
pressure to resistance, and new strategies such as triple
antimalarial combinations may increase the useful thera-
peutic life of existing drugs.
The new drugs in development range from those
with known chemical structures and/or mechanism of
action with enhanced properties, such as tafenoquine
(an 8-aminoquinoline), artefenomel (OZ439) (a syn-
thetic peroxide), and P218 (an antifol); to new chemical
classes such as KAE609 (a spiroindolone) and KAF156
(an imidazolopiperazine) [11]. The threat of potentially
untreatable falciparum malaria is real, and will require
radical action if malaria is to be eliminated before the
available drugs become ineffective [30, 62, 63].
Conclusions
After thousand years of man’s struggle with malaria, the
disease is still an important health problem in the tro-
pics. P. falciparum, the major cause of death from mal-
aria, has developed resistance to all currently used
antimalarials and after substantial improvements in con-
trol in recent years threatens a resurgence. The elimin-
ation of malaria in the greater Mekong subregion, which
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is the major source of drug-resistant parasites, is an ur-
gent priority to avert this threat. New drugs and new
strategies to use the existing drugs are urgently needed
before untreatable falciparum malaria becomes a reality.
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